Intervention

Empagliflozin 10 MG

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 41 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials41

Recruiting7

Common conditions25

Lead sponsors shown15

Clinical trials

41 shown

Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial HypertensionNCT06992440 · 2025-06-26

Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type IINCT06706791 · 2025-04-01

The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1NCT06030843 · 2025-03-01

Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.NCT05879276 · 2024-12-16

A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health RecordNCT06642272 · 2024-10-10

Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With HypertensionNCT06055452 · 2024-01-19

Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart FailureNCT05392764 · 2022-09-10

Role of Finerenone in African American Veterans With Diabetic Kidney DiseaseNCT07155694 · 2026-10-01

NOT_YET_RECRUITING

Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart DiseaseNCT06260059 · 2024-09-17

ACTIVE_NOT_RECRUITING

Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical TrialNCT06094920 · 2024-07-29

Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese PatientNCT06145360 · 2023-12-01

Empagliflozin Versus Vildagliptin in CAD Patients With T2DMNCT06313008 · 2023-08-10

Empagliflozin in Pulmonary Arterial HypertensionNCT05493371 · 2023-03-01

Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney DiseaseNCT05638880 · 2022-12-20

Effect of Empagliflozin on NT-Pro Brain Natriuretic Peptide in Heart Failure Patients With Reduced Ejection FractionNCT05778084 · 2022-12-15

Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection FractionNCT05600387 · 2022-11-05

Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF PatientsNCT06065280 · 2022-11-01

Empagliflozin on Patients With Preserved Heart FailureNCT07112274 · 2022-10-01

Empagliflozin for New On-set Heart Failure Study Regardless of Ejection FractionNCT05556044 · 2022-09-27

Use of SGLT2i in noHCM With HFpEFNCT06401343 · 2022-08-01

Empagliflozin in Hypertrophic CardiomyopathyNCT05182658 · 2022-06-01

ACTIVE_NOT_RECRUITING

Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart FailureNCT05776043 · 2022-03-15

Novel Therapeutics and Endothelial Dysfunction in T1DM PatientsNCT05857085 · 2021-12-15

Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection FractionNCT05139472 · 2021-11-09

SNIFF - Combo INI+EMPA TrialNCT05081219 · 2021-09-14

SGLT2 Inhibitors in Glomerular HyperfiltrationNCT04143581 · 2021-09-03

The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart FailureNCT05042973 · 2021-09-02

The Cardiac Effects of Empagliflozin in Patients With High Risk of Heart FailureNCT05084235 · 2021-09-02

Effect of Empagliflozin on Liver Fat in Non-diabetic PatientsNCT04642261 · 2021-01-01

Renohemodynamic Effects of Combined empagliflOzin and LosARtanNCT04238702 · 2020-11-04

Stress Cardiac Magnetic Resonance of Asymptomatic Type 2 Diabetics with Cardiovascular High Risk to Measure Empagliflozin Impact on Myocardial Blood Flow (CATCH-EM)NCT04541797 · 2020-10-01

ACTIVE_NOT_RECRUITING

REGROUP: Renohemodynamic Effects empaGliflozin in vaRiOUs PopulationsNCT04243850 · 2020-07-01

Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN)NCT03933956 · 2020-01-09

Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney DiseaseNCT04961931 · 2019-01-01

Effect of Empagliflozin on Body Composition and KetonesNCT03877406 · 2018-08-01

Empagliflozin and the Preservation of Beta-cell Function in Women with Recent Gestational DiabetesNCT03215069 · 2018-07-01

Mediterranean Diet, Circuit Resistance Training, Empagliflozin in Elderly With Type 2 Diabetes: a Study ProtocolNCT03560375 · 2018-05-09

Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic EffectsNCT03485092 · 2018-03-16

Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart FailureNCT03200860 · 2017-12-18

Empagliflozin in Heart Failure Patients With Reduced Ejection FractionNCT03198585 · 2017-06-29

Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study)NCT04183868 · 2016-04-01

Common conditions

Leading sponsors

Amsterdam UMC, location VUmc 3 Damanhour University 3 China National Center for Cardiovascular Diseases 2 Jacob Moller 2 The University of Hong Kong 2 University Medical Center Groningen 2 Alexandria University 1 Anita Saraf 1 Central Hospital, Nancy, France 1 Chinese University of Hong Kong 1 Chulalongkorn University 1 Fazaia Ruth Pfau Medical College 1 General and Teaching Hospital Celje 1 Gustavo A Heresi, MD, MS 1 Herlev and Gentofte Hospital 1

Trial status mix

COMPLETED20

RECRUITING7

UNKNOWN7

ACTIVE_NOT_RECRUITING3

WITHDRAWN2

NOT_YET_RECRUITING1

TERMINATED1

Phase mix

PHASE419

PHASE210

PHASE38

NA5

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.